Carfilzomib
Back to searchMolecule Structure
Scientific Name
Carfilzomib
Description of the Drug
Carfilzomib is a proteasome inhibitor used either alone or in conjunction with a chemotherapy regimen to treat patients with relapsed or refractory multiple myeloma.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB08889
http://www.drugbank.ca/drugs/DB08889
Brand Name(s)
Kyprolis
Company Owner(s)
Apotex Inc, Dr Reddys Laboratories Ltd, Onyx Therapeutics Inc A Wholly Owned Sub Of Amgen Inc, Breckenridge Pharmaceutical Inc
Mechanism(s) Of Action
Target Name | Target Type | Action Type | Target ChEMBL ID |
---|---|---|---|
26S proteasome | PROTEIN COMPLEX | INHIBITOR | CHEMBL2364701 |
Clinical Trial(s)
Unichem Links
SureChEMBL | SCHEMBL85165 | |
PharmGKB | PA166165203 | |
DrugBank | DB08889 | |
PubChem: Thomson Pharma | 16812122 | 16658822 |
PubChem | 11556711 | |
LINCS | LSM-45547 | |
Nikkaji | J2.711.864J | |
BindingDB | 50277889 | |
EPA CompTox Dashboard | DTXSID4048690 | |
DrugCentral | 4483 | |
Brenda | 83670 | |
ChemicalBook | CB12520831 | |
Guide to Pharmacology | 7420 | |
rxnorm | KYPROLIS | CARFILZOMIB |
PubChem: Drugs of the Future | 92309411 | |
ChEBI | 65347 | |
ZINC | ZINC000049841054 |